Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: aroundight who wrote (2189)	3/15/1999 12:10:00 PM
From: Joe	Read Replies (1) \| Respond to of 4140

David Flynn, LTK is for low to moderate hyperopia. Clinical trials are ongoing for higher hyperopia. I have heard that when their new instrument is introduced, they will start clinical trials for hyperopia with astigmatism. For myopia, you still would need LASIK, PRK, or soon you could can have the KERA Intacts, an intrastromal implant. VISX is the clear leader with excimer lasers for all the treatment indications, but the stock is a little pricy and driven by sales growth and per procedure revenues. Summit Technology, BEAM, is another stock to look at. It's like VISX but with questionable financials. SNRS is unique. While the other companies may be able to treat hyperopia, they are very invasive procedures. The Sunrise LTK, with extensive patent protection, changes corneal curvature by heating the corneal collagen and making it shrink in the right places and in the right amount to correct vision. There is no cutting, no scraping, no implanting, just a laser that gently warms corneal collagen. Since you have had PRK, you know that if you could have had a procedure that did not require scraping and the corneal bandages and the pain and pain medication you would chose it. So for hyperopes, the choice is an easy one. SNRS has the same kind of revenue model that VISX has. The system is half the price and I think the procedure charge SNRS collects is about half what VISX is charging. (I might be wrong on the procedure charge.) SNRS has submitted data from their clinical trials to FDA in December of last year. We expect that they will go before the Ophthalmic Devices Panel of the FDA in July and they should be able to start selling the product in the U.S. by the end of the year. Good luck, Joe

To: aroundight who wrote (2189)	3/15/1999 1:11:00 PM
From: Makahadan	Respond to of 4140

<<Makahadan, Did your doctor say why SNRS is better?>> i'm really going more on my positive impression of the doc than on my understanding of the differences in the processes. FWIW, and I repeat I am not confident in my understanding, I understand that SNRS process is less invasive and will eventually be adjustable to work on astigmatism. I know we have some eye docs on this thread. Can they correct or amend my understanding with informed expertise? thanks, Daniel B.